{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:32:24Z","timestamp":1793039544826,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Angelini Pharma Espa\u00f1a SLU"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12325-021-01689-8","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T06:03:56Z","timestamp":1617775436000},"page":"2491-2512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Real-World\u00a0Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-6717","authenticated-orcid":false,"given":"Miquel","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rico-Villademoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemente","family":"Garc\u00eda-Rizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"G\u00f3mez-Huelgas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.metabol.2015.04.009","volume":"64","author":"S Rosenbaum","year":"2015","unstructured":"Rosenbaum S, Stubbs B, Ward PB, Steel Z, Lederman O, Vancampfort D. The prevalence and risk of metabolic syndrome and its components among people with posttraumatic stress disorder: a systematic review and meta-analysis. Metabolism. 2015;64:926\u201333.","journal-title":"Metabolism"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1176\/appi.ajp.2012.12050620","volume":"170","author":"D Vancampfort","year":"2013","unstructured":"Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170:265\u201374.","journal-title":"Am J Psychiatry"},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1017\/S0033291713002778","volume":"44","author":"D Vancampfort","year":"2014","unstructured":"Vancampfort D, Correll CU, Wampers M, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med. 2014;44:2017\u201328.","journal-title":"Psychol Med"},{"key":"1689_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/wps.20252","volume":"14","author":"D Vancampfort","year":"2015","unstructured":"Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339\u201347.","journal-title":"World Psychiatry"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/alcalc\/agw040","volume":"51","author":"D Vancampfort","year":"2016","unstructured":"Vancampfort D, Hallgren M, Mugisha J, et al. The prevalence of metabolic syndrome in alcohol use disorders: a systematic review and meta-analysis. Alcohol Alcohol. 2016;51:515\u201321.","journal-title":"Alcohol Alcohol"},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","volume":"20","author":"BWJH Penninx","year":"2018","unstructured":"Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialog Clin Neurosci. 2018;20:63\u201373.","journal-title":"Dialog Clin Neurosci"},{"key":"1689_CR7","volume-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association; 2020."},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon R, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64\u201377.","journal-title":"Lancet Psychiatry"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","volume":"40","author":"L Hirsch","year":"2017","unstructured":"Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40:771\u201381.","journal-title":"Drug Saf"},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/acps.13131","volume":"141","author":"S Mas","year":"2020","unstructured":"Mas S, Gass\u00f3 P, Rodr\u00edguez N, et al. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. Acta Psychiatr Scand. 2020;141:541\u201352.","journal-title":"Acta Psychiatr Scand"},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/archpsyc.58.12.1172","volume":"58","author":"BC Lund","year":"2001","unstructured":"Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58:1172\u20136.","journal-title":"Arch Gen Psychiatry"},{"key":"1689_CR12","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2020. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 20 July 2020."},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/ijerph14030287","volume":"14","author":"S Sharmin","year":"2017","unstructured":"Sharmin S, Kypri K, Khanam M, Wadolowski M, Bruno R, Mattick RP. Parental supply of alcohol in childhood and risky drinking in adolescence: systematic review and meta-analysis. Int J Environ Res Public Health. 2017;14:287.","journal-title":"Int J Environ Res Public Health"},{"key":"1689_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.4088\/JCP.v63n1010","volume":"63","author":"FD Gianfrancesco","year":"2002","unstructured":"Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920\u201330.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2146\/ajhp050144","volume":"63","author":"F Gianfrancesco","year":"2006","unstructured":"Gianfrancesco F, Pesa J, Wang RH, Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health Syst Pharm. 2006;63:431\u201341.","journal-title":"Am J Health Syst Pharm"},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/10401230500464596","volume":"18","author":"F Gianfrancesco","year":"2006","unstructured":"Gianfrancesco F, Wang RH, Nasrallah HA. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Ann Clin Psychiatry. 2006;18:9\u201317.","journal-title":"Ann Clin Psychiatry"},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/01.jcp.0000085404.08426.3a","volume":"23","author":"F Gianfrancesco","year":"2003","unstructured":"Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328\u201335.","journal-title":"J Clin Psychopharmacol"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/bmj.325.7358.243","volume":"325","author":"CE Koro","year":"2002","unstructured":"Koro CE, Fedder DO, L\u2019Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.","journal-title":"BMJ"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4088\/JCP.v63n0902","volume":"63","author":"CJ Kornegay","year":"2002","unstructured":"Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002;63:758\u201362.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR20","doi-asserted-by":"publisher","first-page":"1812284","DOI":"10.4088\/JCP.18m12284","volume":"80","author":"TH Tu","year":"2019","unstructured":"Tu TH, Huang KL, Bai et al. Exposure to second-generation antipsychotics and risk of type 2 diabetes mellitus in adolescents and young adults: a nationwide study in Taiwan. J Clin Psychiatry. 2019;80:1812284.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1592\/phco.24.16.1529.50952","volume":"24","author":"JC Barner","year":"2004","unstructured":"Barner JC, Worchel J, Yang M. Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans. Pharmacotherapy. 2004;24:1529\u201338.","journal-title":"Pharmacotherapy"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","volume":"55","author":"L Citrome","year":"2004","unstructured":"Citrome L, Jaffe A, Levine J, Allingham B, Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004;55:1006\u201313.","journal-title":"Psychiatr Serv"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/j.1525-1497.2004.40126.x","volume":"19","author":"WR Farwell","year":"2004","unstructured":"Farwell WR, Stump TE, Wang J, Tafesse E, L\u2019Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med. 2004;19:1200\u20135.","journal-title":"J Gen Intern Med"},{"key":"1689_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/pds.1092","volume":"14","author":"BL Lambert","year":"2005","unstructured":"Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf. 2005;14:417\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/070674371305800407","volume":"58","author":"J Moisan","year":"2013","unstructured":"Moisan J, Turgeon M, Desjardins O, Gr\u00e9goire JP. Comparative safety of antipsychotics: another look at the risk of diabetes. Can J Psychiatry. 2013;58:218\u201324.","journal-title":"Can J Psychiatry"},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4088\/JCP.v67n0707","volume":"67","author":"JJ Guo","year":"2006","unstructured":"Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry. 2006;67:1055\u201361.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1592\/phco.27.1.27","volume":"27","author":"JJ Guo","year":"2007","unstructured":"Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy. 2007;27:27\u201335.","journal-title":"Pharmacotherapy"},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/aje\/kwj289","volume":"164","author":"BL Lambert","year":"2006","unstructured":"Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol. 2006;164:672\u201381.","journal-title":"Am J Epidemiol"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1176\/appi.ajp.161.9.1709","volume":"161","author":"DL Leslie","year":"2004","unstructured":"Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161:1709\u201311.","journal-title":"Am J Psychiatry"},{"key":"1689_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/01.nmd.0000165292.11527.16","volume":"193","author":"EA Miller","year":"2005","unstructured":"Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis. 2005;193:387\u201395.","journal-title":"J Nerv Ment Dis"},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/pds.1781","volume":"18","author":"MU Yood","year":"2009","unstructured":"Yood MU, DeLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent\u2013results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf. 2009;18:791\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.4088\/JCP.13m08642","volume":"74","author":"L Citrome","year":"2013","unstructured":"Citrome L, Collins JM, Nordstrom BL, et al. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. J Clin Psychiatry. 2013;74:1199\u2013206.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR33","first-page":"5","volume":"6","author":"DA Ollendorf","year":"2004","unstructured":"Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed. 2004;6:5.","journal-title":"MedGenMed"},{"key":"1689_CR34","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.4088\/JCP.v63n1208","volume":"63","author":"JJ Caro","year":"2002","unstructured":"Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135\u20139.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR35","doi-asserted-by":"publisher","first-page":"e1002058","DOI":"10.1371\/journal.pmed.1002058","volume":"13","author":"JF Hayes","year":"2016","unstructured":"Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med. 2016;13:e1002058.","journal-title":"PLoS Med"},{"key":"1689_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.schres.2010.12.007","volume":"126","author":"CH Liao","year":"2011","unstructured":"Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126:110\u20136.","journal-title":"Schizophr Res"},{"key":"1689_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/da.22489","volume":"33","author":"CY Lin","year":"2016","unstructured":"Lin CY, Wu YH, Wang HS, Chen PK, Lin YF, Chien IC. Risk of new onset type II DM in MDD patients receiving second-generation antipsychotics treatment: a nationwide cohort study. Depress Anxiety. 2016;33:435\u201343.","journal-title":"Depress Anxiety"},{"key":"1689_CR38","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/npp.2010.78","volume":"35","author":"J Nielsen","year":"2010","unstructured":"Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients. Neuropsychopharmacology. 2010;35:1997\u20132004.","journal-title":"Neuropsychopharmacology"},{"key":"1689_CR39","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","volume":"174","author":"AP Rajkumar","year":"2017","unstructured":"Rajkumar AP, Horsdal HT, Wimberley T, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174:686\u201394.","journal-title":"Am J Psychiatry"},{"key":"1689_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","volume":"173","author":"TS Stroup","year":"2016","unstructured":"Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry. 2016;173:166\u201373.","journal-title":"Am J Psychiatry"},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.schres.2014.01.043","volume":"154","author":"LL Lipscombe","year":"2014","unstructured":"Lipscombe LL, Austin PC, Alessi-Severini S, et al. Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data. Schizophr Res. 2014;154:54\u201360.","journal-title":"Schizophr Res"},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3371\/CSRP.4.3.2","volume":"4","author":"JM Jerrell","year":"2010","unstructured":"Jerrell JM, McIntyre RS, Tripathi A. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clin Schizophr Relat Psychoses. 2010;4:161\u20138.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.genhosppsych.2012.02.004","volume":"34","author":"JH Hsu","year":"2012","unstructured":"Hsu JH, Chien IC, Lin CH, Chou YJ, Chou P. Hyperlipidemia in patients with schizophrenia: a national population-based study. Gen Hosp Psychiatry. 2012;34:360\u20137.","journal-title":"Gen Hosp Psychiatry"},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/01.jcp.0000150224.38630.ae","volume":"25","author":"BL Lambert","year":"2005","unstructured":"Lambert BL, Chang KY, Tafesse E, Carson W. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J Clin Psychopharmacol. 2005;25:12\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"1689_CR45","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1176\/ajp.2006.163.10.1821","volume":"163","author":"M Olfson","year":"2006","unstructured":"Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L\u2019Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163:1821\u20135.","journal-title":"Am J Psychiatry"},{"key":"1689_CR46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/hup.858","volume":"22","author":"JM Jerrell","year":"2007","unstructured":"Jerrell JM, McIntyre RS. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum Psychopharmacol. 2007;22:361\u20134.","journal-title":"Hum Psychopharmacol"},{"key":"1689_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jpsychores.2012.07.002","volume":"73","author":"EL Wu","year":"2012","unstructured":"Wu EL, Chien IC, Lin CH, Chou YJ, Chou P. Increased risk of hypertension in patients with major depressive disorder: a population-based study. J Psychosom Res. 2012;73:169\u201374.","journal-title":"J Psychosom Res"},{"key":"1689_CR48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1532-5415.2011.03842.x","volume":"60","author":"SC Erickson","year":"2012","unstructured":"Erickson SC, Le L, Zakharyan A, et al. New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J Am Geriatr Soc. 2012;60:474\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"1689_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjopharm.2011.04.006","volume":"9","author":"JJ Jalbert","year":"2011","unstructured":"Jalbert JJ, Daiello LA, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. Am J Geriatr Pharmacother. 2011;9:153\u201363.","journal-title":"Am J Geriatr Pharmacother"},{"key":"1689_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/070674370905400408","volume":"54","author":"S Kisely","year":"2009","unstructured":"Kisely S, Cox M, Campbell LA, Cooke C, Gardner D. An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients. Can J Psychiatry. 2009;54:269\u201374.","journal-title":"Can J Psychiatry"},{"key":"1689_CR51","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/archinternmed.2009.207","volume":"169","author":"LL Lipscombe","year":"2009","unstructured":"Lipscombe LL, L\u00e9vesque L, Gruneir A, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med. 2009;169:1282\u20139.","journal-title":"Arch Intern Med"},{"key":"1689_CR52","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/JGP.0b013e318209dd24","volume":"19","author":"LL Lipscombe","year":"2011","unstructured":"Lipscombe LL, L\u00e9vesque LE, Gruneir A, et al. Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am J Geriatr Psychiatry. 2011;19:1026\u201333.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1689_CR53","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/schbul\/sbm156","volume":"34","author":"TS Stroup","year":"2008","unstructured":"Stroup TS, Geddes JR. Randomized controlled trials for schizophrenia: study designs targeted to distinct goals. Schizophr Bull. 2008;34:266\u201374.","journal-title":"Schizophr Bull"},{"key":"1689_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/acps.12309","volume":"131","author":"C Garcia-Rizo","year":"2015","unstructured":"Garcia-Rizo C, Fernandez-Egea E, Bernardo M, Kirkpatrick B. The thrifty psychiatric phenotype. Acta Psychiatr Scand. 2015;131:18\u201320.","journal-title":"Acta Psychiatr Scand"},{"key":"1689_CR55","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12888-017-1539-0","volume":"17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Liu Y, Su Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017;17:373.","journal-title":"BMC Psychiatry"},{"key":"1689_CR56","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00228-019-02739-5","volume":"75","author":"L Yu","year":"2019","unstructured":"Yu L, Wu S, Deng Y, Lei J, Yu L, Li W. Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis. Eur J Clin Pharmacol. 2019;75:1621\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1689_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pnpbp.2018.01.004","volume":"83","author":"KJ Burghardt","year":"2018","unstructured":"Burghardt KJ, Seyoum B, Mallisho A, Burghardt PR, Kowluru RA, Yi Z. Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:55\u201363.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1689_CR58","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00213-016-4411-x","volume":"233","author":"C Polcwiartek","year":"2016","unstructured":"Polcwiartek C, Vang T, Bruhn CH, Hashemi N, Rosenzweig M, Nielsen J. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology. 2016;233:3663\u201372.","journal-title":"Psychopharmacology"},{"key":"1689_CR59","doi-asserted-by":"publisher","first-page":"l1114","DOI":"10.1136\/bmj.l1114","volume":"365","author":"EK French","year":"2019","unstructured":"French EK, Donihi AC, Korytkowski MT. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ. 2019;365:l1114.","journal-title":"BMJ"},{"key":"1689_CR60","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14740338.2020.1713091","volume":"19","author":"BB Barton","year":"2020","unstructured":"Barton BB, Segger F, Fischer K, Obermeier M, Musil R. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19:295\u2013314.","journal-title":"Expert Opin Drug Saf"},{"key":"1689_CR61","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"1689_CR62","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","volume":"18","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18:208\u201324.","journal-title":"World Psychiatry"},{"key":"1689_CR63","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang Q, Reynolds GP, et al. Metabolic effects of 7 antipsychotics on patients with schizophrenia: a short-term, randomized, open-label, multicenter, pharmacologic trial. J Clin Psychiatry. 2020;81:19m12785.","DOI":"10.4088\/JCP.19m12785"},{"key":"1689_CR64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","volume":"101","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res. 2008;101:273\u201386.","journal-title":"Schizophr Res"},{"key":"1689_CR65","doi-asserted-by":"publisher","first-page":"e0194127","DOI":"10.1371\/journal.pone.0194127","volume":"13","author":"V Bellou","year":"2018","unstructured":"Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. PLoS One. 2018;13:e0194127.","journal-title":"PLoS One"},{"key":"1689_CR66","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40264-015-0339-z","volume":"38","author":"N Fathallah","year":"2015","unstructured":"Fathallah N, Slim R, Larif S, Hmouda H, Ben SC. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38:1153\u201368.","journal-title":"Drug Saf"},{"key":"1689_CR67","doi-asserted-by":"publisher","first-page":"C3","DOI":"10.2337\/diacare.21.3.C3","volume":"21","author":"SM Haffner","year":"1998","unstructured":"Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care. 1998;21:C3-6.","journal-title":"Diabetes Care"},{"key":"1689_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11606-017-4205-9","volume":"33","author":"C Mangurian","year":"2018","unstructured":"Mangurian C, Schillinger D, Newcomer JW, et al. Diabetes screening among antipsychotic-treated adults with severe mental illness in an integrated delivery system: a retrospective cohort study. J Gen Intern Med. 2018;33:79\u201386.","journal-title":"J Gen Intern Med"},{"key":"1689_CR69","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/17425247.2016.1115479","volume":"13","author":"T Suzuki","year":"2016","unstructured":"Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin Drug Deliv. 2016;13:253\u201364.","journal-title":"Expert Opin Drug Deliv"},{"key":"1689_CR70","doi-asserted-by":"publisher","first-page":"pyw038","DOI":"10.1093\/ijnp\/pyw038","volume":"19","author":"T Kishi","year":"2016","unstructured":"Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials. Int J Neuropsychopharmacol. 2016;19:pyw038.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1689_CR71","doi-asserted-by":"publisher","first-page":"361","DOI":"10.9758\/cpn.2018.16.4.361","volume":"16","author":"SC Park","year":"2018","unstructured":"Park SC, Choi MY, Choi J, et al. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis. Clin Psychopharmacol Neurosci. 2018;16:361\u201375.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1689_CR72","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","volume":"176","author":"F Misawa","year":"2016","unstructured":"Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176:220\u201330.","journal-title":"Schizophr Res"},{"key":"1689_CR73","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.schres.2017.12.010","volume":"197","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274\u201380.","journal-title":"Schizophr Res"},{"key":"1689_CR74","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(05)64664-8","volume":"348","author":"AM Walker","year":"1996","unstructured":"Walker AM, Stampfer MJ. Observational studies of drug safety. Lancet. 1996;348:489.","journal-title":"Lancet"},{"key":"1689_CR75","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S2215-0366(15)00541-6","volume":"3","author":"F Rico-Villademoros","year":"2016","unstructured":"Rico-Villademoros F, Calandre EP. Risk of bias in observational studies of interventions: the case of antipsychotic-induced diabetes. Lancet Psychiatry. 2016;3:103\u20134.","journal-title":"Lancet Psychiatry"},{"key":"1689_CR76","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","volume":"27","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2017","unstructured":"H\u00e1lfd\u00e1narson \u00d3, Zo\u00ebga H, Aagaard L, et al. International trends in antipsychotic use: a study in 16 countries, 2005\u20132014. Eur Neuropsychopharmacol. 2017;27:1064\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1689_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","volume":"136","author":"CJ Bachmann","year":"2017","unstructured":"Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136:37\u201351.","journal-title":"Acta Psychiatr Scand"},{"key":"1689_CR78","doi-asserted-by":"publisher","first-page":"18com12123","DOI":"10.4088\/JCP.18com12123","volume":"80","author":"JM Kane","year":"2019","unstructured":"Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80:18com12123.","journal-title":"J Clin Psychiatry"},{"key":"1689_CR79","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487\u201393.","journal-title":"Diabetes Care"},{"key":"1689_CR80","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1689_CR81","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953\u20132041.","journal-title":"J Hypertens"},{"key":"1689_CR82","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamapsychiatry.2016.0538","volume":"73","author":"EH Morrato","year":"2016","unstructured":"Morrato EH, Campagna EJ, Brewer SE, et al. Metabolic testing for adults in a state Medicaid program receiving antipsychotics: remaining barriers to achieving population health prevention goals. JAMA Psychiatry. 2016;73:721\u201330.","journal-title":"JAMA Psychiatry"},{"key":"1689_CR83","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12888-020-02990-6","volume":"20","author":"RA Ali","year":"2020","unstructured":"Ali RA, Jalal Z, Paudyal V. Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: a systematic review. BMC Psychiatry. 2020;20:581.","journal-title":"BMC Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01689-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T02:49:16Z","timestamp":1675133356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01689-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01689-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}